Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Leuk Lymphoma. 2020 Jul;61(7):1728-1731. doi: 10.1080/10428194.2020.1728754. Epub 2020 Feb 20.

Raffaele Palmieri¹, Sarah A Buckley¹, Megan Othus², Anna B Halpern^{1

3}, Mary-Elizabeth M Percival^{1

3}, Bart L Scott^{1

4}, Paul C Hendrie^{3

5}, Pamela S Becker^{1

3}, Vivian G Oehler^{1

3}, Elihu H Estey^{1

3}, Roland B Walter^{1

3

6

7}

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
⁴ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA.
⁵ Seattle Cancer Care Alliance, Seattle, WA, USA.
⁶ Department of Pathology, University of Washington, Seattle, WA, USA.
⁷ Department of Epidemiology, University of Washington, Seattle, WA, USA.

No abstract available

Publication types